← Back to Search

Mutational Analysis as a Prognostic and Predictive Marker of Cardiovascular (CVD) Disease in Patients With Myelodysplasia

N/A
Waitlist Available
Led By Rashmi S Goswani, MD
Research Sponsored by Sunnybrook Health Sciences Centre
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 2 years
Awards & highlights
No Placebo-Only Group

Summary

This study evaluates the relationship between myelodysplastic syndromes (MDS) and cardiovascular disease. MDS patients will be evaluated for the presence of mutations and whether they are associated with an increased risk of heart disease (CVD) and inflammation compared to healthy adults. Patients without symptoms of CVD will receive CT scans to assess for hidden disease and if that is related to their mutations.

Eligible Conditions
  • Cardiovascular Disease
  • Inflammation and Pain
  • Myelodysplastic syndrome
  • Inflammation

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~2 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 2 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Identify any correlation between selected myeloid mutations and/or their VAF with the presence of pre-existing incident or occult CAD
Measure the allelic frequency and type of myeloid cancer-associated mutations in MDS patients diagnostic bone marrow aspirates or slides
Screen for occult and potentially clinically significant CAD in MDS patients by means of coronary CT
Secondary study objectives
Screen for serum inflammatory cytokines in the blood of patients with incident or occult CAD
Track how often newly discovered CAD from coronary CT leads to further intervention or changes in monitoring

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: MDS patientsExperimental Treatment3 Interventions
All Canadian MDS patients on the MDS-database to be included.

Find a Location

Who is running the clinical trial?

Sunnybrook Health Sciences CentreLead Sponsor
681 Previous Clinical Trials
1,565,496 Total Patients Enrolled
Ontario Molecular Pathology Research NetworkUNKNOWN
Queen's UniversityOTHER
374 Previous Clinical Trials
124,380 Total Patients Enrolled
Rashmi S Goswani, MDPrincipal InvestigatorSunnybrook Health Sciences Centre
~64 spots leftby Dec 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top